Zai Lab Limited

Hello, ladies and gentlemen, thank you for standing by and welcome to the XyLab third quarter 2022 financial results conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Billy Cho, Chief Financial Officer of XyLab. who will make introductory comments.

Thank you, operator. Good morning, good evening, and welcome, everyone. Zylab recently issued a press release providing the details of the company's financial results for the third quarter of 2022, as well as some recent product highlights and corporate updates. The press release is available in the investor relations section of the company's website at ir.zylaboratory.com. Today's call will be led by Dr. Samantha Dew, Zylab's founder, chairperson, and chief executive officer. She'll be joined by Josh Smiley, chief operating officer, who will discuss advances in oncology product candidates. And Dr. Harold Reinhart, President and Head of Global Development, Neuroscience, Autoimmune, and Infectious Diseases, who will speak about the progress we've made in those three therapeutic areas. And I will discuss the performance of our marketed products, conclude with comments on our financial results. Additional executives will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, ZyLab will be making certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our business plans and objectives and timing and success of our clinical trials, our sales and revenue forecasts for our products and product candidates, regulatory applications, and commercial launches. But forward-looking statements are not guarantees of future performance, and therefore we should not put unduly lies upon them. These statements are subject to numerous risks and uncertainties, and actual results could differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. At this time, it is my pleasure to turn the call over to Xylex founder, chairperson, and chief executive officer, Dr. Samantha Du.

Thank you, Billy. Hello, everyone, and thank you all for joining us today. The third quarter marked another period of strong execution across our company, including revenue growth, continuing and significant progress in our mid- and late-stage pipeline and business development. Over the next few quarters and years ahead, I have little doubt that we'll continue to strengthen the company through growth and productivity. Before I get into specific details, I would like to say that I'm very proud of all of our employees across the globe, especially regarding Zai's ability to deliver time and time again, no matter what challenges present themselves. We have built a great culture at Zai focused on innovation to bring transformative medicine to address unmet medical needs. Fundamentally, we have a very productive year so far, and we are anticipating finishing 2022 having delivered on no other key corporate priorities. We continue to demonstrate resilience revenue growth in the third quarter, despite some ongoing challenges from COVID and certain reasons in China. We expect to deliver significant revenue growth for years to come. Our broad-lead and late-stage development candidates continue to see strong advances, highlighted by our agreement with the NMPA on development plans for the corrective for bridging studies with schedule 3 in China. On the business development front, we recently announced a strategic collaboration with CISM for TVEC, which strengthens our ability to address unmet medical needs in women's cancer in China. In addition, we expect to realize significant synergies given our existing commercial infrastructure and strategic positioning in this important disease area. In summary, we remain confident in the fundamental strengths of our business and our ability to create significant shareholder value. With that, I would like to turn the call over to Josh. Josh?